Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study asks: does aspirin work in patients with low platelets?

NCT ID NCT04912505

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well a daily low-dose aspirin works in people who have both immune thrombocytopenia (low platelets) and heart disease. Only 4 adults took part. Researchers measured platelet function after aspirin to see if the standard dose is enough to prevent blood clots. The study is complete, but the small size means the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aspirin
What this could lead to
If successful, this could help doctors understand if standard aspirin dosing is enough to protect against blood clots in people with immune thrombocytopenia.
What could go wrong
This was a very small, early-phase study with only 4 participants, so results may not apply to everyone. The study is already completed, and no new treatment is being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

4 people

The number who actually took part.

Started

Jan 2023

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adult patients * non-treated immune thrombocytopenia or immune thrombocytopenia with stable treatment (at least 1 month) * treated with aspirin daily for a cardiovascular disease; stable platelet count \< 100 x 109/L * at least one month following an arterial thrombosis * no other antiplatelet drug and anticoagulant * female patient with childbearing potential must have acceptable method of birth control * affiliated or benefiting from public health insurance Exclusion Criteria: * opposition to participate * adults under guardianship or other legal protection * deprived of their liberty by judicial or administrative decision * pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction thrombocytopenic purpura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Purpura, thrombocytopenic

Contacts and locations

Locations

  • Toulouse Hospital

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.